Novonesis Rebounds: Sharpened Focus & Value‑Based Deals Propel Growth
Investor optimism rises for NOVONESIS (NASDAQ: NOVOZYMES) B as it pivots to core enzyme therapies, value‑based contracts and lean manufacturing, promising margin lift and growth.
4 minutes to read









